Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC lowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas

Acta Neuropathologica

Volumn 126, Issue 4, 2013, Pages 603-605

  Brunn, Anna ^a   Nagel, Inga ^b   Montesinos Rongen, Manuel ^a   Klapper, Wolfram ^c   Vater, Inga ^b   Paulus, Werner ^d   Hans, Volkmar ^e   Blümcke, Ingmar ^f   Weis, Joachim ^g   Siebert, Reiner ^b   Deckert, Martina ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e EVANGELISCHES KRANKENHAUS   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6;

ADVERSE OUTCOME; BCL 6 GENE; BRAIN LYMPHOMA; CANCER PROGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LETTER; ONCOGENE MYC; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; TRANSLATION REGULATION;

CENTRAL NERVOUS SYSTEM NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-6; TUMOR MARKERS, BIOLOGICAL;

EID: 84885481315     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1169-7     Document Type: Letter

References (8)

1. Dominguez-Sola D, Victora GD, Ying CY et al (2012) The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol 13:1083-1091
2. Green TM, Young KH, Visco C et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460-3467
3. Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253-2263
4. Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452-3459
5. Montesinos-Rongen M, Brunn A, Bentink S et al (2008) Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 22:400-405
6. Montesinos-Rongen M, Siebert R, Deckert M (2009) Primary lymphoma of the central nervous system: just DLBCL or not? Blood 113:7-10
7. Montesinos-Rongen M, Schafer E, Siebert R, Deckert M (2012) Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol 124:905-906
8. Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947